AbbVie ABBV stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

If you are wondering whether AbbVie at around US$224 per share still offers value, or if most of the opportunity is already ...

AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

On November 5, Piper San‍dler analyst David Amsellem raised the price target on AbbVie Inc. (NYSE:ABBV) from⁠ $284 to $289 while maintaining an Over‌weight rating on the stock foll‌owing its ...

Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive. AbbVie is also an excellent dividend stock. 10 stocks we like better than ...

Buy AbbVie (ABBV) stock? See more on its 2025 EPS growth outlook from Skyrizi/Rinvoq, valuation at 14.4x FY27, key risks, and breakout targets.

A meaningful portion of AbbVie’s ABBV revenues comes from its oncology franchise. Initially anchored by blood cancer drugs ...